Oral Lactobacillus Crispatus LCr86 Reduces Nugent Score and Improves Vaginal Microecology in Women With Intermediate Vaginal Microbiota

Exclusion Criteria

• •1. Those who are currently being treated for severe cardiovascular system, immune system, respiratory system, gastrointestinal tract/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease, tumor and malignant.
• •2. The subjects who treated for vaginal or urinary tract infection as of within 3 months (e.g., candidiasis, trichomonas infection, gonorrhea, chlamydial infection, etc.).
• •3. The subjects with vaginal or urinary tract bleeding, or abnormality.
• •4. The subjects who has been given antibiotics, antimicrobial agents, steroids, immunosuppressants, estrogen-based drugs (pneumonia-related drugs are allowed) within 4 weeks of visit 1 (but those who used them within 2 weeks of visit 1 cannot participate in the test).
• •5. The subjects who has consumed health functional foods related to improving immune function and vaginal health.
• •6. The subjects who has administered probiotics and prebiotics within two weeks based on visit 1 or has continuously administered or ingested fermented milk and lactobacillus products.
• •7. Allergic constitution or hypersensitivity to known components of the study drug.
• •8. The subjects who has received salivary treatment for sedimentation, women's cleansers, vaginal sanitizers, left fumigation, and vaginal health within two week of screening visit.
• •9. The subjects with unregulated hypertension (above 160mmHg or 90mmHg of blood pressure).
• •10. The subjects who AST (GOT) or ALT (GPT) is at least three times the normal limit of the testing agency.
• •11. The subjects who are sensitive or allergic to the ingredients of this human-applied test food.
• •12. Subjects who are pregnant, breastfeeding, or planning to conceive within three months.
• •13. If the daily alcohol intake is more than 20g.
• •14. Excessive smokers (≥20 pieces/day).
• •15. The subjects who has participated in another interventional clinical trial within three month of the commencement of this trial or who has a plan to participate in another interventional clinical trial (including a human application test) after the commencement of this human application test.
• •16. The subjects who is deemed inappropriate by the human application test testers for this human application test.
• •17. Other vaginitis: Trichomonas vaginalis (TV) infection or fungal infection.